Sponsor

Seelos Therapeutics will sponsor and participate in Wonderland, the world’s leading psychedelic event

-Seelos’ SLS-002 (racemic intranasal ketamine) is believed to be the only drug in the psychedelic class currently being developed specifically to treat the symptoms of suicidality associated with major depression.

-Seelos senior management will sponsor the press breakfast on friday november 4e at 8:30 am and take part in 2 round tables on saturday november 5e.

NEW YORK, October 27, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, today announced that it will sponsor and will be participating in Wonderland, the world’s leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, Florida of November 3rd at 5e.

Seelos will sponsor the Press breakfast with Seelos Therapeutics on friday november 4e at 8:30 a.m. ET to discuss their SLS-002 (racemic intranasal ketamine) program, which is currently enrolling patients in Part 2 of the directed, randomized, double-blind, placebo-controlled clinical study. The purpose of the study is to evaluate the efficacy, safety and tolerability of repeated doses of SLS-002, in addition to standard of care, on symptoms of major depression and suicidality in patients assessed as being at imminent risk of suicide .

In addition, Seelos will participate in a round table entitled: Route Dose; Does dissociation correlate with antidepressant/analgesic effects on saturday november 5e at 10:40 a.m. ET.

Also, Saturday at 1:10 p.m. ETRaj Mehra, Ph.D., Chairman and CEO of Seelos and Tim WhitakerMD, Chief Medical Officer of Seelos, will be interviewed by Dean BurnettPh.D., in a fireside chat titled: Seelos Therapeutics: new investigational program to treat acute suicidal ideation and behavior in patients with major depressive disorder.

For more information, agenda and tickets to Wonderland, please visit: https://microdose.buzz/wonderland/

If you or someone close to you has thoughts of suicide, please seek immediate medical attention, go to the nearest emergency room, call Suicide and crisis lifeline at 988 or 1-800-273-8255 (TALK).

About Wonderland Miami

Wonderland Miami offers the psychedelic medicine industry a unique in-person convergence of business, science, music and emerging technologies. Fostering creative and professional growth, Wonderland Miami is the premier destination for the psychedelic medicine industry. The event is a thought leadership platform and an opportunity to connect with influential leaders in science, politics and business. It acts as a launchpad for innovative content related to the psychedelic medicine space, with musical showcases and documentary screenings, providing compelling entertainment and collaboration opportunities for attendees. Wonderland is synonymous with real events with high quality programming in some of the world’s most exciting locations and breathtaking locations.

About Dean Burnettdoctorate

Dean Burnett is a Doctor of Neuroscience who has spent many years lecturing and teaching postgraduate psychiatry to students around the world. However, his real passion lies in writing and communicating, and has since become an internationally bestselling science author, as well as a much-requested pundit, journalist and commentator for mainstream media and beyond. He specializes in brain function and mental health science.

He is the best-selling author silly brain (published in more than 30 countries), and the next emotional ignorancePosted in January 2023.

For more information on Dr. Burnett, please visit: https://www.deanburnett.com/

About SLS-002

SLS-002 is a racemic intranasal ketamine with two new investigational drug applications for the treatment of acute suicidal ideation and behavior in major depressive disorder and post-traumatic stress disorder. SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects. Seelos seeks to address an unmet need for a therapy to treat suicidality in the United States with SLS-002. Traditionally, antidepressants have been used in this setting, but many existing treatments are known to contribute to an increased risk of suicidal thoughts in certain circumstances, and if effective, often take weeks for full therapeutic effect. manifests. . The clinical development program for SLS-002 includes two parallel studies in healthy volunteers (Phase I), followed by pivotal registration studies after a meeting with the FDA. Based on information gathered from the Agency for Health Care Research and Quality databases, there were more than 1,000,000 emergency room visits for suicide attempts in 2019 in the United States. only. Experimental studies suggest that ketamine has the potential to be a rapid and effective treatment for intractable depression and suicidal tendencies.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapies to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. . The company’s strong portfolio includes several late-stage clinical assets targeting indications such as acute suicidal ideation and behavior (ASIB) in major depressive disorder (MDD) or post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson’s disease, other psychiatric disorders and movement disorders as well as orphan diseases.

For more information, please visit our website: http://seelostherapeutics.comthe contents of which are not incorporated herein by reference.

Forward-looking statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include, among other things, those regarding the belief de Seelos that SLS-002 is the only drug enrolled in a registrational clinical study to measure its effects on patients with ASIB in MDD. These statements are based on Seelos’ current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks associated with Seelos’ business include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies and not obtaining marketing authorizations for its product candidates, the risk that prior clinical results will not be replicated in future studies and clinical trials, the risks that the results of clinical studies will not meet all or part of the endpoints of a clinical study and that the data generated from these studies may not support a regulatory submission or approval, the risks associated with implementing a new business strategy, the risks associated with raising capital to fund its development plans and ongoing operations, the risks associated current share price of Seelos, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos’ periodic filings with Secu rities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove to be correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if we subsequently make them available on our website or otherwise. We undertake no obligation to update, change or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Contact information:

Antoine Marciano
Head of Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2n/a Floor
New York, NY 10022
(646) 293-2136
[email protected]
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike MoyerGeneral Manager
LifeSci Advisors, LLC
250 West 55th Street, Suite 3401
New York, NY 10019
(617) 308-4306
[email protected]

SOURCE Seelos Therapeutics, Inc.

.

#Seelos #Therapeutics #sponsor #participate #Wonderland #worlds #leading #psychedelic #event

Related Articles

Back to top button